The DST Knockout NCI-H1299 Polyclonal Cells comprise a heterogeneous population of human NCI-H1299 lung carcinoma cells subjected to CRISPR/Cas9-mediated disruption of the DST gene, generating a pooled loss-of-function model for dystonin. As a polyclonal knockout product, this cell population represents a versatile tool for studying dystonin-dependent cytoskeletal processes without requiring single-cell cloning, maintaining biological diversity while ensuring target-gene inactivation across the pool. This format is particularly suited for functional screens, bulk assays, and applications where clonal variability is mitigated by population-level representation.
The host cell line, NCI-H1299, is an extensively characterized model of metastatic non-small cell lung cancer (NSCLC). Derived from a lymph node metastasis of a lung adenocarcinoma, these cells exhibit adherent epithelial morphology and are null for the tumor suppressor p53 while retaining wild-type KRAS, making them a standard platform for investigating molecular mechanisms of advanced lung carcinoma. Their metastatic origin and genetic profile render them especially relevant for studies of invasion, cytoskeletal dynamics, and drug response in cancer biology.
DST encodes dystonin, a giant plakin family cytoskeletal linker protein that orchestrates the integration of intermediate filaments, actin, and microtubules. Dystonin physically interacts with keratin intermediate filaments (K5/K14), vimentin, actin, microtubules, integrin ??4, plectin, and BPAG2 (BP180), mediating crosslinking and mechanical stability. Its expression is regulated by p63 and Notch signaling, linking epithelial differentiation cues to cytoskeletal architecture. Knockout of dystonin disrupts these interactions, impairing intermediate filament organization, actin cytoskeleton reorganization, microtubule stability, and focal adhesion dynamics, with downstream consequences for cell adhesion, migration, and intracellular trafficking.
In the context of NCI-H1299 cells, disruption of dystonin is anticipated to profoundly alter cytoskeletal integrity and mechanical responsiveness. Given the metastatic nature of this NSCLC line, loss of dystonin may compromise cell adhesion and directional migration, processes critical for invasion and metastasis. Additionally, dystonin??s role in tethering signaling complexes at focal adhesions suggests that its knockout could modulate integrin-mediated signal transduction and sensitivity to cytoskeleton-targeted therapeutics, providing a valuable system to explore the intersection of cytoskeletal mechanics and oncogenic signaling.
This knockout polyclonal population is suited for a range of experimental applications, including analysis of cytoskeletal organization via immunofluorescence and western blotting for dystonin, keratins, and actin; assessment of cell migration and invasion using transwell assays; and evaluation of drug sensitivity to cytoskeleton-disrupting agents. It serves as a platform for transcriptomic profiling (RNA-seq) to delineate dystonin-dependent gene networks and for phenotypic screening in lung cancer metastasis models. For further details, including lot-specific knockout validation and culture recommendations, please contact Ascent Research.
